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(Atrial fibrillation (AF) causes substantial morbidity and mortal-
ty. It may be triggered and sustained by either reentrant or
onreentrant electrical activity. Human atrial cellular refractory
eriod is shortened in chronic AF, likely aiding reentry. The ionic
nd molecular mechanisms are not fully understood and may
nclude increased inward rectifier K current and altered Ca2
andling. Heart failure, a major cause of AF, may involve arrhyth-
ogenic atrial electrical remodeling, but the pattern is unclear in
umans. Beta-blocker therapy prolongs atrial cell refractory pe-car-
rtal-
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547-5271/$ -see front matter © 2008 Heart Rhythm Society. All rights reservedolecular mechanisms are unclear. The search for drugs to sup-
ress AF without causing ventricular arrhythmias has been aided
y basic studies of cellular mechanisms of AF. It remains to be
een whether such drugs will improve patient treatment.
EYWORDS Arrhythmias (mechanisms); Atrial fibrillation; Beta-
locker; Electrical remodeling; Heart failure; Ion current; Refrac-
ory period; Transmembrane action potential
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iod; a potentially antiarrhythmic influence, but the ionic and rights reserved.c-
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thatlectrophysiological mechanisms of human
trial fibrillation and their study in single
trial cells
trial fibrillation (AF) is the most common sustained 
iac arrhythmia. It causes substantial morbidity and mo
ty. The majority of atrial premature beats that initiate
riginate from focal ectopic electrical activity in the pu
ary veins (PVs). AF is sustained by single- or mul
ircuit intra-atrial reentry and/or focal ectopy, and the l
ay be reentrant or nonreentrant.1 Nonreentrant mecha-
isms include abnormal automaticity (AA) and trigge
ctivity. AA is the premature firing of action poten
APs) because of abnormal diastolic membrane depolar
ion (Figure 1A) and is favored by, for example, -adren-
rgic stimulation or decreased vagal activity. Triggered 
ivity is premature firing due to after-depolarizations. Th
ay be early (EADs), occurring during repolarization 
avored by AP prolongation, or delayed (DADs), occur
fter an AP and favored by intracellular Ca2 overload
Figure 1A). Reentry is rapid circuitous activation caused
nidirectional conduction block and favored by premat
mpulses, heterogeneity and shortening of the effective
ractory period (ERP), and slowing of conduction veloc
 (Figure 1B). Several electrophysiological parameters th
ay affect AF genesis and maintenance have been m
Antony J. Workman received British Heart Foundation Basic Science
ectureship award BS/06/003. Address reprint requests and correspon-
ence: Dr. Antony J. Workman, British Heart Foundation Glasgow Cardio-
ascular Research Centre, Faculty of Medicine, University of Glasgow, 126
niversity Place, Glasgow G12 8TA, United Kingdom. E-mail address:
.J.Workman@clinmed.gla.ac.uk. (Received December 13, 2007; aured in human atrial isolated cells. The cellular ERP2 and
P maximum upstroke velocity, Vmax (Figure 1C), contrib-
te to myocardial ERP and , respectively, so their redu
ion could promote reentry by shortening its wavelengt
Figure 1B). Cellular arrhythmic depolarizations (CADs3;
igure 1D) may represent AA, EADs, or DADs, with
ential involvement in nonreentrant mechanisms.
trial cellular electrical remodeling in AF
trial myocardial electrical and mechanical activity 
tructure adapt, or remodel, in response to a variet
iseases and other stimuli. For example, congestive h
ailure (CHF) may involve electrical remodeling, atrial
ation, and interstitial fibrosis, each potentially predispos
o AF. Once AF occurs, the rapid atrial rate causes 
lectrical remodeling that promotes AF, so AF is auto
etuating. In goats, induced AF progressively shortened 
trial ERP and AF interval over 24 hours, which reduce
eentry  and increased AF vulnerability.4 Maximal ERP
hortening may precede maximal AF duration, but the 
hortening contributes to the AF substrate. In our lab
ory, a similar ERP shortening was found in atrial 
solated from patients with chronic AF (igure 1C). This
as associated with impaired ERP rate adaptation, shor
ng and triangulation of the AP and no change in Vmax.2 The
hortened AP permitted full repolarization at the fast 
ypically encountered in AF and thus prevented the d
arization of the maximum diastolic potential (MDP), 
as observed in sinus rhythm (SR).2 This effect on MDP
ight limit Ca2 overload in the remodeled atrium, but the
RP changes favor reentry. The ERP is largely determined
y the AP duration (APD), which depends on a delicate
alance of inward and outward ion currents flowing through
. doi:10.1016/j.hrthm.2008.01.016
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S2 Heart Rhythm, Vol 5, No 6, June Supplement 2008variety of membrane protein channels, pumps, and ex-
hangers. Therefore, an understanding of the mechanisms of
uman AF-induced atrial electrical remodeling requires
nowledge about precise changes in each of these currents,
nd their contributions to the AP, in AF.
otential ionic mechanisms of electrical
emodeling in AF
any human atrial ion currents have so far been studied in
igure 1 Electrophysiological mechanisms of arrhythmias and their
tudy in human atrial cells. A: Representation of premature APs (*) from
A, EADs, or DADs. B: Premature impulse divides at functional or
natomical obstacle, blocks at tissue with normal (left side), but conducts
ith short (right) ERP and reenters previously inexcitable zone.  
avelength;   conduction velocity. C: Original APs stimulated in an
trial cell from a patient in SR or in AF by conditioning pulses (S1) and
remature test pulses (S2). ERP (↔)  longest S1-S2 failing to produce S2
esponse of amplitude 80% of S1. D: Original APs stimulated by a pulse
rain in the presence of 0.05 M isoproterenol (ISO), producing CADs (●).
he * may represent AA. Panels C and D are based on data in references
and 3 with permission from Elsevier.F; they are shown in Table 1. The inward rectifier K surrent (IK1) is the main determinant of the resting potential
Vm). Other currents contribute, including acetylcholine-
ctivated K current (IKACh), Na, K pump current (Ip),
nd possibly ATP-sensitive K current (IKATP). IK1 and
KACh also contribute to terminal repolarization. There is
onsensus that chronic AF is associated with increased
ensity of IK1 (Table 1). Furthermore, despite decreased
arasympathetic-regulated IKACh, a constitutively active
CA) IKACh, not requiring its endogenous agonist, is induced
n AF (Figure 2). A single study on Ip, from our laboratory,
howed no change in AF, and changes in IKATP are variable.
he reported increases in IK1 and CA IKACh were most
rominent (with enhanced inward current) at voltages more
egative than the AP voltage range. However, enhanced
utward IK1 has also been reported, within the AP voltage
ange,5,6,8 which may contribute to the APD and ERP short-
ning in AF. Increased IK1 should also hyperpolarize Vm;
hile difficult to ascertain in human atrial isolated cells
ince the “chunk” isolation method may depolarize them,
his has been reported in atrial trabeculae.6 The AP fires
hen depolarization sufficient to drive Vm to threshold
ctivates inward Na current (INa), causing the regenerative
nd rapid AP upstroke; the larger INa, the faster Vmax. A
ingle study reported no change in INa density in AF, con-
istent with Vmax (Table 1), although its inactivation voltage
ependency was altered. Partial, or early, repolarization
ollows the AP upstroke, via activation of a transient out-
ard K current (ITO) and the ultrarapid delayed rectifier
 current (IKur). AF consistently and markedly reduced
TO, but data for IKur are equivocal (Table 1). The ITO
eduction may contribute to AP triangulation in AF, as
hown by blocking ITO with 4-aminopyridine (4-AP).2
owever, its contribution to the APD90 and ERP is unclear
ince 4-AP also blocks IKur, although mathematical model-
ng suggested a negligible role.34 The AP plateau is main-
ained by inward, L-type Ca2, current (ICaL), which is
onsistently and markedly reduced in chronic AF (Table 1),
espite increased single-channel open probability.35 Such
CaL reduction depresses the AP plateau, consistent with
cute effects of nifedipine2 or simulated ICaL reduction,34
lthough its contribution alone to the shortening of the
PD902,34 or ERP2 may be small. Mid/late repolarization
esults from activation of IKur as well as from the rapid (IKr)
nd slow (IKS) delayed rectifiers, which are balanced by
nward Na-Ca2 exchange current (INa/Ca) following the
Ca2]i transient. INa/Ca also underlies the transient inward
urrent responsible for DADs. However, any role for these
urrents in human AF remodeling is presently unclear, since
ata are either equivocal or unavailable (Table 1). AA
esults from decreased outward and/or increased inward
iastolic currents, including INa/Ca and the “funny” current
If). However, data on If are also lacking.
Human PV isolated cell electrophysiology has not yet
een studied. Chronic atrial tachypacing (AT) in dogs pro-
uced APD shortening in PV cells that was qualitatively
imilar to that in atrial cells and also produced similar
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S3Workman et al Cellular Bases for Human AFhanges in IK1, ITO, and ICaL.36 However, a current that may
e analogous to human CA IKACh was increased more
trongly in PV cells than in atrial cells, perhaps favoring PV
eentry.37 The relative importance of reentrant versus non-
eentrant activity to PV arrhythmogenesis, either before or
fter AF remodeling, is unknown.1
Atrial electrical activity is intricately linked with cellular
nd subcellular Ca2 fluxes, particularly via INa/Ca. Intra-
ellular Ca2 handling is altered in AF, although human
ata are sparse. In canine atrial cells, acute AT, analogous to
paroxysm of AF, abruptly increases diastolic [Ca2]i, a
otential trigger of the remodeling process. Chronic AT, by
ontrast, markedly decreased the [Ca2]i transient ampli-
ude,38 perhaps reflecting protection from [Ca2]i overload.
his may result from a deficient trigger function of the
arkedly reduced ICaL, since sarcoplasmic reticular Ca2
ontent was preserved.38 Human AF was associated with a
otentially arrhythmogenic increase in the frequency of
a2 sparks and waves.39 This may represent sarcoplasmic
eticular Ca2 leak due to ryanodine receptor hyperphos-
horylation.40
Whether the combined ionic changes so far established
n human AF can account for the associated AP changes is
nclear and will require the aid of mathematical models.
ne such model suggested that the combined IK1, ITO, and
CaL changes could explain the AP changes,34 although in
he dog, concurrent [Ca2]i changes were required.38 An-
ther model suggested a major contribution from the IK1
ncrease to the stabilization of reentry.41
otential molecular mechanisms in AF:
enetic and nongenetic
any atrial ion current changes in human AF are accom-
anied by, and often considered to be caused by, altered
issue expression of the ion channel pore-forming -sub-
able 1 Human atrial cellular electrophysiological changes asso
uman atrial cell
lectrophysiological measurement Chronic AF Po
RP 22 ↔
PD90 2
2,5–7
↔
PD50 ↔
2,6 17 ↔
P Vmax ↔
2
↔
K1 1
2,5,6,8–12
↔
KACh 1
5 26,9,10,12 ↔
A IKACh 1
10,12 ND
p ↔
13 ND
KATP 2
14 115 ND
Na ↔
5 ND
TO 2
2,5,8,16,17
↔
Kur (ISUS) 2
8,16
↔
2,5,17
↔
CaL 2
2,5,7,11,18–21 1
CaL %1 by  stimulation 1
18–21
↔
CaL %1 by 5-HT 2
7 ND
Na/Ca, INa/H, IKr, IKs, ICl(swell), ICaB, If NDA ND
Arrows show direction of change relative to “controls.”
 atrial dilation only; NDA  no data available. See text for definitionsnits that carry them, for example, increased Kir2.1 (carries AK1) and decreased Kv4.3 (ITO).11 However, there are some
ntriguing and controversial exceptions. Protein levels of
CaL -subunits were decreased by 40%–55% in three stud-
es,35,42,43 in line with ICaL reduction, but were unchanged in
our others.11,20,21,44 Also, despite increased CA IKACh in
F (Table 1), the Kir 3.1 protein level was decreased.43 The
pparent discrepancies between changes in ion current den-
ity and protein expression suggest post-translational mod-
fication or altered channel regulation. The magnitude of
CaL is influenced by a balance between channel phosphor-
lation by kinases and dephosphorylation by phosphatases.
hronic AF upregulated phosphatase type-2A-C, reducing
CaL without requiring reduced channel protein.20 Similarly,
nduction of CA IKACh in human AF resulted from abnormal
rotein kinase- (PK-) C function12 (Figure 2C).
AF may be a heritable disorder: positive family history
as identified in 5% of patients with AF.45 Several genetic
utations have been associated with familial AF, mainly for
 channels. Most are gain-of-function mutations, increas-
ng IKs, IKr, or IK1 and expected to shorten ERP and promote
eentry, although an IKur loss-of-function mutation might
rolong ERP.45 However, such mutations occur in other
iseases, for example, dilated cardiomyopathy and long-
T, short-QT, and Brugada syndromes, some of which are
omorbidities for AF. Nevertheless, it seems that genetic
ariants are involved in the pathogenesis of AF in a pro-
ortion of cases.
eurohumoral involvement in AF
F can result from a sympathetic/parasympathetic imbal-
nce. Furthermore, neurohumoral activation in CHF, an
mportant cause of AF, increases circulating levels of cat-
cholamines, angiotensin, and endothelin (ET-1). Beta-ad-
energic stimulation from catecholamines may promote
ADs, by increasing ICaL and Ca2-induced Ca2 release.
with AF, ventricular dysfunction, and drug therapy
AF
CHF, LVSD, and/or
atrial dilation Chronic 1-blocker therapy
NDA 13,22,31
123,24 ↔25,26 122,31
↔
23,24 226 ↔3,31
NDA ↔31
223 ↔*27 232
223 NDA
NDA NDA
NDA NDA
↔
24 NDA
NDA NDA
126 2*27,28 231,32
↔
25,26
↔*28 2*27 ↔31,32
2 229 ↔25,30 2*27 ↔3,7,22,31,33
229,30 ↔3,22
229 17,33
NDA NDAciated
st-CS
22
22
22
22
9,22
9
A
A
A
A
22
22
18
↔
2
22
A
AF remodeling potentiated the relative increase in ICaL
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S4 Heart Rhythm, Vol 5, No 6, June Supplement 2008roduced by -stimulation (Table 1). We demonstrated that
T-1 had no direct effect on ICaL, APD, or ERP in human
trial cells. However, it abolished isoproterenol-induced in-
reases in ICaL, APD50, and CADs (Figure 1D), with no
ffect on ERP.3 Thus, ET-1 might exert an antiadrenergic
ntiarrhythmic influence in the atria of patients with CHF.
erotonin (5-HT) is released from platelets aggregating in
tatic blood in fibrillating atria. We demonstrated that 5-HT
ay be arrhythmogenic in human atrium, by increasing ICaL
nd producing CADs, without affecting ERP.33 Atrial re-
odeling by AF may protect from these effects, however,
ince they were attenuated in cells from patients with
hronic AF7 (Table 1).
ostoperative AF: Is there a predisposing
trial cellular electrophysiological substrate?
F is common in patients after cardiac surgery (CS).
igure 2 Induction of constitutively active acetylcholine-activated K
urrent, CA IKACh, in human AF. Single-channel IK1 and CA IKACh cur-
ents (A) and mean (standard error) open probabilities (B), recorded at
120 mV in atrial cells from patients in SR (open symbols) and AF (solid
ymbols). *P .05 versus SR. C: Potential signaling mechanism of in-
reased CA IKACh in AF. In SR, IKACh may require channel phosphoryla-
ion by calmodulin-dependent PK II (CaMKII), PKG, and PKC.12 In AF,
A IKACh may result from upregulation of PKC.12 Panels A and B are
ased on data in reference 10 with permission from Lippincott Williams &
ilkins.ost-CS AF is independently predicted by old age, pre-CS mF, and pre-CS P-wave changes. Therefore, pre-CS atrial
ellular electrophysiology could influence the propensity for
ew-onset AF post-CS, which is an issue presently under
ebate. An early study showed an association between
ost-CS AF and an enhanced pre-CS ICaL,18 potentially
rrhythmogenic post-CS, when catecholamines are ele-
ated. However, we recently demonstrated, by contrast, that
re-CS ICaL, AP parameters, or ERP were not predictive of
ost-CS AF.22 Furthermore, no other ion current that was
easured, nor the ICaL response to -stimulation, was
ifferent between patients with and without post-CS AF
Table 1). Some currents remain to be studied, but it
ppears that the electrically remodeled state caused by
hronic AF (Table 1) is not present pre-CS in the atrial
ells of patients who develop new-onset post-CS AF.
eart failure–induced atrial remodeling
F is common in patients with CHF, and left ventricular
ystolic dysfunction (LVSD) substantially increases the risk
f AF. It is unclear whether atrial cellular electrical remod-
ling, in patients in SR, contributes to this predisposition to
F. The available human data are scarce and inconsistent
Table 1) and are compounded by inevitable variability in
he patients’ disease states and drug treatments. Atrial cel-
ular electrical remodeling has been demonstrated in canine
odels of chronic ventricular tachypacing (VTP)-induced
HF. AF was invariably promoted, but the remodeling
attern differed from AF: atrial ERP was unchanged or
ncreased, IK1 was not increased, both ITO and IKS were
ecreased, ICaL was only moderately decreased, and INa/Ca
as increased.46,47 The increased INa/Ca might favor a trig-
ered origin of AF in this model. CHF also caused atrial
brosis, and while the ionic remodeling reversed after ceas-
ng VTP, the fibrosis and AF persistence did not.46 Thus,
trial electrical remodeling may contribute to AF genesis
ut was not necessary for its maintenance in this model.
uman CHF or LVSD were associated with variable
hanges in APD, and cellular ERP has not been studied
Table 1). Human atrial ionic changes in CHF or LVSD may
e expected to differ from those in chronic AF, with de-
reased IK1 and increased ITO, decreased or unchanged ICaL,
nd a decreased ICaL response to -stimulation so far re-
orted (Table 1). The pattern may depend on the degree of
trial dilation, which itself may cause ionic remodeling
Table 1). Moreover, CHF- and AF-induced atrial remodeling
nteract. In dogs, this interaction was complex, not cumulative:
hronic AT, imposed on a CHF-remodeled atrium, caused
oderate ERP shortening, IK1 increase, and ICaL decrease but
id not further remodel ITO, IKS, or INa/Ca.47 No comparative
uman atrial data could be found.
trial remodeling by chronic drug therapy
trial electrophysiology remodels in response not only to
iseases and aging but also to long-term drug treatments;
o-called pharmacological remodeling.31 This was origi-
ally demonstrated in rabbits: treatment with the 1-blocker
etoprolol caused an adaptational prolongation of the atrial
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S5Workman et al Cellular Bases for Human AFPD, maximally after 6 days.48 Beta-blockers are increas-
ngly used to treat AF and HF. We demonstrated that in
atients in SR, 1-blocker treatment for 7 days was inde-
endently associated with prolonged atrial cell APD90 and
RP22,31 (Figure 3A, 3B), and not with ICaL.22 The ITO was
educed (Figure 3C), and ISUS was unchanged (Table 1).
igure 3 Pharmacological remodeling of human atrial cell electrophys-
ology by 1-blocker therapy. A: APs and ERP (↔); B: mean (standard
rror) APD at 50% and 90% repolarization (APD50 and APD90) and ERP;
: transient outward K currents, recorded in single atrial myocytes from
atients in SR, treated with a 1-blocker 7 days (solid symbols) versus
hose in SR who were not treated with a -blocker (open symbols). *P
.05 versus non -blocker. D: Correlation between atrial cell ERP and
atient’s atenolol dose/body weight. Heart rate 75 bpm. Dashed lines
ndicate the 95% confidence interval. Panels A and C are based on data in
eference 31 with permission from Elsevier.reliminary data from our group suggest that the ITO reduc-ion does not involve altered voltage dependency or kinet-
cs32 or altered ion channel expression49 and that IK1 is also
educed.32 Recent subgroup analysis revealed a significant
orrelation between ERP and atenolol dose (Figure 3D),
uggesting that the ERP prolongation is at least partly
aused, directly or indirectly, by the atenolol treatment.
uch ERP prolongation might contribute to the antiarrhyth-
ic effects of beta-blockers, although a potentiation by
hronic -blockade of effects of 5-HT on ICaL (Table 1) and
ADs33 could also oppose them.
ow research on cellular bases for human AF
s driving new therapeutic strategies
raditional ERP-prolonging drugs, which are used to inhibit
eentry, act by blocking IKr. This is problematic because IKr
xists in the ventricle as well as atrium, which risks ven-
ricular EADs and fibrillation. IKur and IKACh are considered
o be atrium specific, so their block might prolong ERP in
trium only, depending on secondary ionic effects. How-
ver, targeting ion channel regulation may be preferable to
on channel block. Altering the PKC pathway that induces
A IKACh in chronic AF12 might avoid undesirable effects
f inhibiting parasympathetic-regulated IKACh on sinoatrial
ode and bladder. Blocking the phosphatase-induced ICaL
ecrease caused by AF20 is another possibility. Moreover,
de-remodeling,” in theory, might be better than such “anti-
emodeling” since blocking potentially protective adapta-
ions may be risky. Pharmacological targeting of nonreen-
rant mechanisms of AF also may be considered.
AF is a highly complex, multifactorial, and dynamic
isorder with differing characteristics and etiologies among
ndividuals. As such, it presents an enormous challenge for
he development of drugs for its effective and safe treat-
ent. Current basic research is driving the search for new
rugs. Several drugs, including IKur and IKACh blockers, are
ntering clinical trials. It remains to be seen whether they
ill improve patient treatment.
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